[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Phathom Pharmaceuticals Inc (PHAT)

Phathom Pharmaceuticals Inc (PHAT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 969,833
  • Shares Outstanding, K 79,756
  • Annual Sales, $ 175,110 K
  • Annual Income, $ -221,250 K
  • EBIT $ -97 M
  • EBITDA $ -93 M
  • 60-Month Beta 0.57
  • Price/Sales 5.57
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 105.75% (+14.10%)
  • Historical Volatility 58.95%
  • IV Percentile 25%
  • IV Rank 13.72%
  • IV High 398.00% on 05/14/25
  • IV Low 59.29% on 08/20/25
  • Expected Move (DTE 5) 1.47 (12.09%)
  • Put/Call Vol Ratio 13.60
  • Today's Volume 146
  • Volume Avg (30-Day) 376
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 29,137
  • Open Int (30-Day) 24,944
  • Expected Range 10.69 to 13.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.15
  • Number of Estimates 1
  • High Estimate $-0.15
  • Low Estimate $-0.15
  • Prior Year $-0.90
  • Growth Rate Est. (year over year) +83.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.73 +24.91%
on 04/30/26
13.66 -11.01%
on 04/20/26
+0.35 (+2.96%)
since 04/08/26
3-Month
9.73 +24.91%
on 04/30/26
14.39 -15.50%
on 02/26/26
-0.42 (-3.34%)
since 02/06/26
52-Week
2.33 +421.89%
on 05/09/25
18.31 -33.59%
on 12/23/25
+9.87 (+431.00%)
since 05/08/25

Most Recent Stories

More News
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal...

PHAT : 12.16 (-0.57%)
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

~1.35 million total VOQUEZNA ® prescriptions filled to date $58.3 million in Q1 net revenues, a 104% increase year-over-year Q1 operating expenses of $61.8 million; non-GAAP operating expenses...

PHAT : 12.16 (-0.57%)
Phathom's Path to Profitability Looks Clear, but the Market Already Stopped Caring

Barchart Research What to Expect from PHAT Earnings PHAT Generated April 29, 2026 Current Price $11.78 EPS Estimate $$-0.27 Consensus Rating Strong Buy Average Move 7.42% Phathom's Path to Profitability...

PHAT : 12.16 (-0.57%)
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical...

PHAT : 12.16 (-0.57%)
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal...

PHAT : 12.16 (-0.57%)
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Over 1.1 million total VOQUEZNA ® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024 Q4 operating...

PHAT : 12.16 (-0.57%)
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 12.16 (-0.57%)
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 12.16 (-0.57%)
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

FLORHAM PARK, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 12.16 (-0.57%)
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal...

PHAT : 12.16 (-0.57%)

Business Summary

Phathom Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel treatments for gastrointestinal diseases. The company's product pipeline consists of vonoprazan, which are in clinical stage. Phathom Pharmaceuticals Inc. is based in Buffalo...

See More

Key Turning Points

3rd Resistance Point 12.86
2nd Resistance Point 12.62
1st Resistance Point 12.39
Last Price 12.16
1st Support Level 11.93
2nd Support Level 11.69
3rd Support Level 11.46

See More

52-Week High 18.31
Fibonacci 61.8% 12.21
Last Price 12.16
Fibonacci 50% 10.32
Fibonacci 38.2% 8.43
52-Week Low 2.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.